Klinikum Bad Bramstedt GmbH
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
The Klinik für Rheumatologie und Immunologie at Klinikum Bad Bramstedt is investigating Hypereosinophilic Syndrome, a rare blood disorder, through trials that compare a new subcutaneous biologic with standard care.
- Evaluation of depemokimab versus placebo
- Assessment of efficacy in uncontrolled disease
This work reflects the site’s commitment to advancing therapies for hematologic conditions.
Immune System Diseases
Researchers are exploring immune modulation in Systemic Sclerosis, aiming to reduce disease activity by testing a novel antibody formulation delivered subcutaneously.
- Use of efgartigimod PH20 SC in adult patients
- Measurement of skin sclerosis improvement
The trial underscores the department’s focus on innovative immune‑targeted treatments.
Skin and Connective Tissue Diseases
The clinic conducts studies on connective‑tissue disorders, specifically Systemic Sclerosis, to evaluate new agents that may slow skin thickening and enhance patient outcomes.
- Co‑formulation with rHuPH20 to improve delivery
- Placebo‑controlled assessment of skin fibrosis
These investigations highlight the site’s dedication to improving care for patients with skin and connective tissue disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Argenx1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Bad Bramstedt GmbH
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients with Systemic Lupus Erythematosus | Alumis Inc. | Phase II | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol | 1 | Unknown | — | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.